Welcome to our dedicated page for IMMUCELL /DE/ SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IMMUCELL /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IMMUCELL /DE/'s regulatory disclosures and financial reporting.
ImmuCell Corporation reported strong growth for the three and six months ended June 30, 2026, driven by its First Defense® calf health products. Product sales for the first half rose to $17.5 million, up 20.9% year over year, with domestic revenue increasing and international sales declining.
Net income for the first half increased to $3.8 million from $1.9 million, helped by a $2.0 million settlement with a former contract manufacturer and lower Re-Tain® development spending after the decision to cease seeking FDA approval. Gross profit improved in dollars but margin compressed as costs of goods sold grew faster than sales, reflecting higher raw material costs, manufacturing inefficiencies and the reclassification of Re-Tain® facility costs into production.
Operating cash flow strengthened to $6.6 million, boosting cash and equivalents to $8.9 million while debt declined modestly to about $8.3 million. The company is reallocating its former Re-Tain® facility to expand First Defense® capacity, planning roughly $8.0 million of related investments over 12–18 months, and remains highly dependent on two major customers and colostrum supply.
ImmuCell Corporation reported significantly improved results for the quarter ended June 30, 2026. Revenue grew 11.5% to $7.2 million, driven by higher distributor volumes and pricing, with distributor out-the-door volume up 28%. Net income rose to $1.8 million (basic and diluted EPS $0.20), compared to $0.5 million (EPS $0.06) a year earlier, aided by a $2.0 million one-time settlement from a former contract manufacturer, recorded as other operating income.
Gross margin was 34%, pressured by lower manufacturing volumes, scrap from a purchased material quality issue, and costs shifted from the discontinued Re-Tain® program. Adjusted EBITDA increased to $2.7 million from $1.4 million in the prior-year quarter. Cash and cash equivalents were $8.9 million as of June 30, 2026, up from $3.8 million at year-end, supported by $6.6 million of operating cash flow in the first half.
The company’s share of U.S. calves receiving a scour biological reached 19%. ImmuCell is executing a two-phase First Defense® capacity expansion, with planned investments of approximately $3.5 million in freeze-drying capacity and $4.5 million in colostrum processing, expected to be financed with cash on hand and cash from operations.
ImmuCell Corporation reported preliminary, unaudited sales showing strong growth in 2026. Total product sales for the three months ended June 30, 2026 were $7.2 million, up 11.5% from $6.4 million a year earlier, driven by a 27.7% increase in domestic sales to $6.2 million. International sales for the quarter declined to $1.0 million from $1.6 million, a 38.9% decrease. For the first six months of 2026, total product sales reached $17.5 million, a 20.9% increase compared to $14.5 million in 2025, with domestic sales of $16.0 million and international sales of $1.6 million. Product-wise, Q2 2026 Tri-Shield First Defense sales were $4.9 million, up 8.3%, while Dual-Force and other sales were $2.3 million, up 19.1%. Management plans to discuss full financial results on a conference call on August 14, 2026.
ImmuCell Corp director and CEO Paul Francis Olivier te Boekhorst reported buying additional company stock. On June 18, 2026, he made an open-market purchase of 8,000 shares of ImmuCell common stock at $9.495 per share, bringing his direct holdings to 17,785 shares.
ImmuCell Corporation held its 2026 annual stockholder meeting by webcast and conference call, with 7,397,695 common shares present, representing more than 81% of eligible votes. Stockholders elected seven directors to one-year terms, each receiving over 5.16 million votes in favor with relatively few votes withheld.
Investors approved a non-binding advisory resolution on executive compensation, with 4,793,553 votes for and 92.4% of votes cast in favor. Another stockholder matter was also approved with 4,689,407 votes for and 90.39% support among votes cast. Stockholders approved an amendment to the Certificate of Incorporation regarding officer exculpation, receiving 4,851,019 votes for, which represented 53.62% of total shares outstanding.
They also ratified the Audit Committee’s selection of Wipfli LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 7,344,196 votes for, 14,645 against and 38,854 abstentions, reflecting 99.28% support among votes cast.
ImmuCell Corporation outlined a manufacturing capacity expansion focused on its flagship First Defense® product line. The Board authorized a program that shifts resources away from the previously planned in-house Re-Tain® production toward expanded First Defense® output.
The first phase will start immediately, renovating the former Re-Tain® facility and installing a new, higher-capacity freeze dryer. This phase is expected to take about 12 months and cost approximately $3.5 million. A second phase will repurpose additional Re-Tain® equipment and add automation to further expand First Defense® colostrum processing, with the goal of reliably meeting expected customer demand.
ImmuCell Corporation reported strong first-quarter 2026 results, highlighted by double-digit growth and improved profitability. Product sales rose 28.4% to $10.4 million, lifting gross margin to 45.0%. Net income increased to $1.9 million, or $0.21 per share, compared with $1.4 million, or $0.16 per share, a year earlier.
The company generated $3.4 million of free cash flow, raising cash to $6.8 million as of March 31, 2026, while maintaining solid inventory. ImmuCell also received a net $2 million payment from settling disputes with a former contract manufacturer and increased manufacturing output from about 380,000 to more than 450,000 units per month.
ImmuCell Corporation reported strong first-quarter 2026 growth, with higher sales and profitability. Product sales reached $10.36 million, up 28.4% from $8.07 million a year earlier, driven mainly by higher volumes and price increases in its First Defense® line. Net income rose to $1.94 million from $1.45 million, and basic and diluted earnings per share increased to $0.21 from $0.16. Gross profit improved to $4.66 million as cost of goods sold grew more slowly than revenue, helped by price actions and manufacturing efficiencies. Operating cash flow more than doubled to $3.57 million, boosting cash and cash equivalents to $6.81 million while total debt edged down to $8.70 million. The company also changed useful-life estimates on certain idle Re-Tain® assets, reducing quarterly depreciation by about $0.1 million. After quarter-end, ImmuCell entered a Settlement Deed under which Norbrook Laboratories agreed to pay $2.0 million, resolving a prior development and supply agreement.
ImmuCell Corporation filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to update the exhibit list only. The amendment adds a previously filed Loan Agreement with Maine Community Bank as Exhibit 10.43, corrects and clarifies descriptions and “incorporated by reference” notations for several executive compensation and plan documents, and refiles the 2025 Stock Option and Incentive Plan to match the version in the April 24, 2026 proxy statement. Updated CEO and CFO certifications are also included. The company states that its audited financial statements and other disclosures from the original filing are unchanged.
ImmuCell Corporation entered into a new settlement agreement with Norbrook Laboratories on May 8, 2026. The companies signed a Settlement Deed that resolves and releases all claims related to their 2019 Development Services and Commercial Supply Agreement, which expired March 31, 2026. Under this Settlement Deed, Norbrook will pay ImmuCell $2,000,000, providing a one-time cash benefit to ImmuCell. The agreement is governed by Northern Ireland law, contains confidentiality undertakings, and explicitly states it is not an admission of liability or wrongdoing by either party.